Cardiovascular Systems Inc. (CSII) Drops 5.17% on February 08

Equities Staff |

Cardiovascular Systems Inc. (CSII) was one of the Russell 2000's biggest losers for Monday February 08 as the stock slid 5.17% to $8.62, a loss of $-0.47 per share. Starting at an opening price of $9.01 a share, the stock traded between $8.50 and $9.01 over the course of the trading day. Volume was 213,745 shares over 1,998 trades, against an average daily volume of 620,312 shares and a total float of 32.7 million.

The losses send Cardiovascular Systems Inc. down to a market cap of $281.85 million. In the last year, Cardiovascular Systems Inc. has traded between $41.28 and $8.02, and its 50-day SMA is currently $13.32 and 200-day SMA is $21.42.

Cardiovascular Systems Inc is a medical technology company. It is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases.

Cardiovascular Systems Inc. is based out of St. Paul, MN and has some 597 employees. Its CEO is Scott R. Ward / David L. Martin.

For a complete fundamental analysis analysis of Cardiovascular Systems Inc., check out Equities.com’s Stock Valuation Analysis report for CSII. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…